Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:18:29.784Z.
Calculation as of: 2026-10-06T18:18:29.784Z.
Quote observation: 2026-10-06T18:15:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64600f38e310d2eb3cd81a0b95bf77f6abd31b9de5548b9cdd3f3c9d46967593
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
PROCEPT BioRobotics Corporation
Market Cap
$986.61M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.68M
EBITDA Yield
20.53%
TTM Avg
16.68%
3Y Avg
16.68%
5Y Avg
16.68%
Market Cap
$984.18M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$977.87M
EBITDA Yield
8.75%
TTM Avg
9.22%
3Y Avg
7.66%
5Y Avg
6.32%
Market Cap
$1.01B
EBITDA Yield
N/A
TTM Avg
50.22%
3Y Avg
50.22%
5Y Avg
50.22%
Market Cap
$1.02B
EBITDA Yield
3.58%
TTM Avg
3.47%
3Y Avg
3.47%
5Y Avg
3.47%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $986.61M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $987.18M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $987.68M | 20.53% | 16.68% | 16.68% | 16.68% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $984.18M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $977.87M | 8.75% | 9.22% | 7.66% | 6.32% |
| Vor Biopharma Inc. (VOR)vs › | $999.00M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | 50.22% | 50.22% | 50.22% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 3.58% | 3.47% | 3.47% | 3.47% |
| Savara Inc. (SVRA)vs › | $954.96M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
